A $355 million initial payment will go to Alentis for a drug aimed at rare kidney and liver diseases.

CSL and Alentis Therapeutics have partnered to develop and commercialize lixudebart, a potential first-in-class therapy for rare kidney and liver diseases. CSL will pay Alentis $355 million upfront and up to $1.2 billion in milestones. Lixudebart is in Phase 2 trials for AAV-RPGN and will be tested for FSGS and PSC. CSL will fund further trials and share global profits. According to the companies, lixudebart has shown promising results in early trials.

President Trump's administration signed drug-pricing agreements with nine mid-sized pharmaceutical companies, including Astellas Pharma, Teva, and UCB, to lower U.S. drug prices under the MFN proposal. Companies agreed to reduce prices and invest $19.6B in U.S. manufacturing, with some contributing APIs to a government reserve. The deals cover 89% of the branded drug market, expanding beyond initial Big Pharma focus.

CSL (ASX:CSL; USOTC:CSLLY) has agreed with the U.S. government to lower drug prices and invest $1.5 billion in U.S. manufacturing. The deals include pricing adjustments for Medicaid and new therapies, and a manufacturing expansion in Illinois. The company expects no material impact in fiscal 2027.

Nomad Foods (NOMD) outlined growth plans at its Investor Day, highlighting opportunities in fish, vegetables, chicken, pizza, and ice cream. The company aims for EUR 550M in adjusted free cash flow from 2027-2029, with EUR 200M-225M in savings. It plans to increase manufacturing capacity and reduce external production. Nomad expects high-single-digit inflation in 2027, primarily due to fish costs, and will mitigate impacts through productivity and pricing strategies.

NextEra Energy (NYSE:NEE) and partners were selected to develop Project Star, a $22 billion energy campus in Texas with 6.47 GW capacity. The project, expected to start delivering power by 2029, will serve a large data center and the grid. NextEra's earnings and debt levels are noted, with the company trading at a forward P/E of 18.85x. Hedge fund interest in NextEra has increased, but the project's financial impact on the company remains unclear.

Stifel raised Zscaler's price target to $235 from $200, citing its AI prospects. The firm maintained a Buy rating after Zscaler's analyst day, where it outlined its strategy and set a fiscal 2031 ARR target of $8B-$10B. Management reaffirmed its fiscal 2027 targets and discussed the importance of securing AI with zero-trust architecture.